FLT3 and acute myeloid leukemia: Higher response rates against hematologic malignancies were observed, in particular when the Aurora inhibitor exhibited a secondary anticancer pharmacology; for example, the inhibition of another oncogenic driver of hematologic cancers such as activated FLT3 in AML.